Last reviewed · How we verify
Intravenous etoposide/cisplatin
Etoposide and cisplatin work together as a chemotherapy combination: etoposide inhibits topoisomerase II to prevent DNA unwinding, while cisplatin creates DNA crosslinks, both leading to cancer cell death.
Etoposide and cisplatin work together as a chemotherapy combination: etoposide inhibits topoisomerase II to prevent DNA unwinding, while cisplatin creates DNA crosslinks, both leading to cancer cell death. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.
At a glance
| Generic name | Intravenous etoposide/cisplatin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Chemotherapy combination (topoisomerase II inhibitor + platinum alkylating agent) |
| Target | Topoisomerase II (etoposide); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Etoposide is a topoisomerase II inhibitor that stabilizes the enzyme-DNA complex, preventing DNA replication and transcription. Cisplatin is a platinum-based alkylating agent that forms covalent crosslinks with DNA, causing strand breaks and apoptosis. Together, this combination provides synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Germ cell tumors
- Lymphomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Secondary malignancy
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (PHASE1, PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC (PHASE1)
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous etoposide/cisplatin CI brief — competitive landscape report
- Intravenous etoposide/cisplatin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI